Drug Money

In bad times, a good IPO births a new unicorn

After a long time, Indian pharma is at its lowest ebb, in stocks and sentiments. But Ahmedabad’s Eris Lifesciences beat the odds. Valued at Rs 8070 crore, it’s a pharma company that is making the domestic market look promising once again

unicorn-1999549_1280-2.jpg

When the bourses closed last evening, Amit Bakshi was worth Rs 3,225 crore and Eris Lifesciences, a pharmaceutical company he founded 10 years ago, became a legitimate unicorn. The most profitable, fastest-growing pharma company in five years with the handsomest return on capital employed—the descriptors have been glowing, even as the industry prospects have dimmed of late. The Indian pharma index has been consistently down since 2016, its first decline in five years. And the pall of the US regulatory inspections and warnings hang heavy…

To access this content, you must purchase Quarterly, or log in if you are a member.

Read the full story now. Subscribe to The Ken

Stories on The Ken are available only for its subscribers. Join us now to get instant access.

Have an account?

Related stories

More stories in /Analysis/Business & /Healthcare

See all in AnalysisBusiness & Healthcare

This story is exclusively for premium subscribers. Subscribe now to get access.

Read the full story now. Subscribe to The Ken

Why should I pay for reading your stories?

Lots of effort We go to lengths to put in time and resources required to get the most factual, honest stories out there.

Advertising independent Our primary allegiance will always be to our readers. We won't be swayed by our advertisers and investors.

We can't do all of this by giving away our journalism for free and selling our readers by the thousands to advertisers.

Get premium access